GlassScriptPhysician profile
Patricia Freidel
NPI 1417282138
$7,555.53
in general payments reported to CMS, 2019-2025
36 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $1,147 · 2021: $1,342 · 2022: $1,311 · 2023: $1,422 · 2024: $1,261 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,097.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,039.02 | 2019-2025 | Farxiga, Bevespi Aerosphere, Fasenra |
| Abbvie INC. | $1,009.56 | 2019-2024 | |
| Pfizer INC. | $565.55 | 2019-2025 | |
| Lilly USA, LLC | $522.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $356.42 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $321.26 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $303.44 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Allergan, INC. | $221.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.80 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $202.45 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $196.41 | 2019-2023 | |
| Novo Nordisk INC | $190.87 | 2019-2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $176.41 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $154.56 | 2023-2024 | Cologuard Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Freidel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.